Bellevue Group AG Acquires 81,786 Shares of Altimmune, Inc. (NASDAQ:ALT)

Bellevue Group AG grew its holdings in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 9.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 945,446 shares of the company's stock after acquiring an additional 81,786 shares during the period. Bellevue Group AG owned 1.33% of Altimmune worth $6,817,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ALT. Barclays PLC increased its holdings in Altimmune by 93.0% in the 3rd quarter. Barclays PLC now owns 155,741 shares of the company's stock worth $956,000 after acquiring an additional 75,064 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Altimmune in the third quarter worth approximately $674,000. B. Riley Wealth Advisors Inc. increased its stake in shares of Altimmune by 12.9% in the third quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company's stock worth $144,000 after purchasing an additional 2,687 shares in the last quarter. 180 Wealth Advisors LLC bought a new stake in shares of Altimmune during the 4th quarter valued at $78,000. Finally, Hennion & Walsh Asset Management Inc. lifted its stake in shares of Altimmune by 18.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 205,590 shares of the company's stock valued at $1,482,000 after buying an additional 31,482 shares in the last quarter. Hedge funds and other institutional investors own 78.05% of the company's stock.

Analyst Upgrades and Downgrades

ALT has been the subject of a number of analyst reports. Stifel Nicolaus started coverage on Altimmune in a research note on Wednesday, January 8th. They issued a "buy" rating and a $18.00 price target for the company. HC Wainwright reiterated a "buy" rating and set a $12.00 target price on shares of Altimmune in a research report on Thursday, April 3rd. Finally, William Blair reissued a "market perform" rating on shares of Altimmune in a report on Friday, March 14th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $20.83.

Altimmune Trading Up 11.6 %

Shares of Altimmune stock opened at $5.77 on Friday. The firm has a market cap of $444.37 million, a PE ratio of -3.72 and a beta of 1.13. The stock has a 50 day moving average of $5.16 and a 200 day moving average of $6.65. Altimmune, Inc. has a 12 month low of $3.55 and a 12 month high of $11.16.

Altimmune (NASDAQ:ALT - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. As a group, equities research analysts forecast that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Gregory L. Weaver acquired 10,000 shares of the company's stock in a transaction on Thursday, March 13th. The stock was bought at an average cost of $5.20 per share, with a total value of $52,000.00. Following the completion of the purchase, the chief financial officer now directly owns 10,000 shares of the company's stock, valued at $52,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 4.10% of the stock is currently owned by company insiders.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

Want to see what other hedge funds are holding ALT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Altimmune, Inc. (NASDAQ:ALT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.